Immix Biopharma Amends ATM Program, Increasing Potential Offering to $100 Million
Summary
Immix Biopharma, Inc. has amended its At-The-Market (ATM) offering agreement, raising the maximum aggregate offering price to $100 million, significantly increasing potential future dilution.
Key Events
-
ATM Program Amended
Immix Biopharma, Inc. entered into Amendment No. 1 to its At-The-Market Offering Agreement with Citizens JMP Securities, LLC, originally dated June 3, 2025.
-
Offering Capacity Increased
The maximum aggregate offering price under the ATM program has been increased to $100,000,000, providing the company with greater capital raising potential.
-
Prospectus Supplement Filed
A prospectus supplement relating to this expanded offering was filed concurrently on March 25, 2026, under the existing S-3 registration statement (File No. 333-292665).
Analysis
This 8-K filing details an amendment to Immix Biopharma's existing At-The-Market (ATM) offering agreement, originally established on June 3, 2025. The key change is the increase in the potential aggregate offering price to $100,000,000. This substantial increase in the ATM program's capacity, representing a significant portion of the company's current market capitalization, signals a considerable potential for future dilution as the company may sell shares into the market from time to time. The concurrent filing of a prospectus supplement finalizes the terms for this expanded program, providing the company with enhanced flexibility for capital raises.
At the time of this filing, IMMX was trading at $9.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.8M. The 52-week trading range was $1.34 to $11.61. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.